MX2020001055A - Vacuna contra la malaria. - Google Patents

Vacuna contra la malaria.

Info

Publication number
MX2020001055A
MX2020001055A MX2020001055A MX2020001055A MX2020001055A MX 2020001055 A MX2020001055 A MX 2020001055A MX 2020001055 A MX2020001055 A MX 2020001055A MX 2020001055 A MX2020001055 A MX 2020001055A MX 2020001055 A MX2020001055 A MX 2020001055A
Authority
MX
Mexico
Prior art keywords
î1⁄4g
subject
polypeptide
seq
dose
Prior art date
Application number
MX2020001055A
Other languages
English (en)
Inventor
Katie Ewer
Adrian V S Hill
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1712092.4A external-priority patent/GB201712092D0/en
Priority claimed from GBGB1718337.7A external-priority patent/GB201718337D0/en
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2020001055A publication Critical patent/MX2020001055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a una composición que comprende un polipéptido que comprende, o consiste en, la secuencia de aminoácidos de SEQ ID NO: 1. o una secuencia que tiene al menos 80 %, 85 %, 90 %, 95 %, 98 % o 99 % de identidad de secuencia respecto a SEQ ID NO. 1(R21) en donde dicho polipéptido está en forma de una particula pseudoviral (VLP), en donde dicha partícula comprende menos del 10 % de la proteína antigénica de superficie de la hepatitis B libre. para usarse en la inmunización de un sujeto humano susceptible a una infección de Plasmodium falciparum, caracterizado porque dicha composición es administrable en un régimen de dosificación de al menos una dosis de 1 pg a 20 pg de R21 por administración para un sujeto de al menos 18 años de edad, o al menos una dosis de 0.5 pg a 10 pg de R21 por administración para un sujeto menor de 18 años de edad. La invención también se refiere a kits, métodos y usos.
MX2020001055A 2017-07-27 2018-07-27 Vacuna contra la malaria. MX2020001055A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1712092.4A GB201712092D0 (en) 2017-07-27 2017-07-27 Malaria vaccine
GBGB1718337.7A GB201718337D0 (en) 2017-11-06 2017-11-06 Malaria vaccine
PCT/GB2018/052122 WO2019021013A1 (en) 2017-07-27 2018-07-27 ANTIMALARIAL VACCINE

Publications (1)

Publication Number Publication Date
MX2020001055A true MX2020001055A (es) 2020-10-28

Family

ID=63143276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001055A MX2020001055A (es) 2017-07-27 2018-07-27 Vacuna contra la malaria.

Country Status (8)

Country Link
US (1) US20200207811A1 (es)
EP (1) EP3658575A1 (es)
KR (1) KR20200032169A (es)
CN (1) CN111148754A (es)
BR (1) BR112020001586A2 (es)
MX (1) MX2020001055A (es)
PH (1) PH12020500194A1 (es)
WO (1) WO2019021013A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114062675A (zh) * 2021-10-13 2022-02-18 东莞市莞城医院 基于队列的cTfh细胞对乙肝疫苗长期免疫效果的实验方法
EP4422676A1 (en) * 2021-10-25 2024-09-04 Novavax AB Malaria vaccine formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2945649B1 (en) * 2013-01-22 2018-12-12 Oxford University Innovation Limited Composition and uses thereof

Also Published As

Publication number Publication date
US20200207811A1 (en) 2020-07-02
BR112020001586A2 (pt) 2020-08-11
PH12020500194A1 (en) 2020-10-19
WO2019021013A1 (en) 2019-01-31
KR20200032169A (ko) 2020-03-25
CN111148754A (zh) 2020-05-12
EP3658575A1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
JP2016539946A5 (es)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
JP2016128513A5 (es)
JP2015214545A5 (es)
WO2018193063A3 (en) NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS
IL276210B2 (en) MERS-COV vaccine
EA018765B1 (ru) Векторы и конструкции для доставки гриппозного антигена
JP2020528911A5 (es)
TW201920236A (zh) 用於對ｈｂｖ產生免疫反應之類病毒粒子
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
PH12020500194A1 (en) Malaria vaccine
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака
EP3715359A1 (en) Cd4 helper t cell epitope fusion peptide and vaccine therewith
MX2010006984A (es) Vacunas contra la malaria.
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
JP2018536002A5 (es)
WO2015095167A3 (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
MX2021004907A (es) Vacuna de ibv 4/91 con proteina espicular heterologa.
JP7271433B2 (ja) 免疫賦活薬、免疫療法用医薬組成物、ならびにその調製および使用
Meseda et al. Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines
KR20120032486A (ko) 면역화 요법용 발현 벡터로서의 수포성 구내염 바이러스의 상이한 혈청형
MX2021004859A (es) Vacuna de ibv h52 con proteina espicular heterologa.
JP2023012539A (ja) 経鼻ｂ型肝炎ワクチン組成物およびその製造方法